Current state and future directions in the therapy of ALS
L Tzeplaeff, S Wilfling, MV Requardt, M Herdick - Cells, 2023 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
affecting upper and lower motor neurons, with death resulting mainly from respiratory failure …
affecting upper and lower motor neurons, with death resulting mainly from respiratory failure …
New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
JS Jiang, Y Wang, M Deng - Frontiers in pharmacology, 2022 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …
[HTML][HTML] Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series
Abstract Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with high
mortality and morbidity rate affecting both upper and lower motor neurons (MN). Muscle …
mortality and morbidity rate affecting both upper and lower motor neurons (MN). Muscle …
Microglial crosstalk with astrocytes and immune cells in amyotrophic lateral sclerosis
M Calafatti, G Cocozza, C Limatola… - Frontiers in …, 2023 - frontiersin.org
In recent years, biomedical research efforts aimed to unravel the mechanisms involved in
motor neuron death that occurs in amyotrophic lateral sclerosis (ALS). While the main …
motor neuron death that occurs in amyotrophic lateral sclerosis (ALS). While the main …
Microglia and astrocytes in amyotrophic lateral sclerosis: disease-associated states, pathological roles, and therapeutic potential
Simple Summary Amyotrophic lateral sclerosis (ALS) is a disease characterized by the
death of motor neurons that results in progressive muscle weakness and paralysis …
death of motor neurons that results in progressive muscle weakness and paralysis …
Therapeutic targeting of ALS pathways: Refocusing an incomplete picture
NJ Maragakis, M de Carvalho… - Annals of Clinical and …, 2023 - Wiley Online Library
Numerous potential amyotrophic lateral sclerosis (ALS)‐relevant pathways have been
hypothesized and studied preclinically, with subsequent translation to clinical trial. However …
hypothesized and studied preclinically, with subsequent translation to clinical trial. However …
Oxidative stress in the brain and retina after traumatic injury
AK Ryan, W Rich, MA Reilly - Frontiers in neuroscience, 2023 - frontiersin.org
The brain and the retina share many physiological similarities, which allows the retina to
serve as a model of CNS disease and disorder. In instances of trauma, the eye can even …
serve as a model of CNS disease and disorder. In instances of trauma, the eye can even …
Status of ALS treatment, insights into therapeutic challenges and dilemmas
M Khamaysa, PF Pradat - Journal of Personalized Medicine, 2022 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is an extremely heterogeneous disease of motor
neurons that eventually leads to death. Despite impressive advances in understanding the …
neurons that eventually leads to death. Despite impressive advances in understanding the …
Macrophage migration inhibitor factor (MIF): potential role in cognitive impairment disorders
L Zeng, P Hu, Y Zhang, M Li, S Li, A Luo - Cytokine & Growth Factor …, 2024 - Elsevier
Macrophage migration inhibitory factor (MIF) is a cytokine in the immune system,
participated in both innate and adaptive immune responses. Except from immune cells, MIF …
participated in both innate and adaptive immune responses. Except from immune cells, MIF …
Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
L Martinez-Gonzalez, A Martinez - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder caused by
motoneuron death with a median survival time of 3–5 years since disease onset. There are …
motoneuron death with a median survival time of 3–5 years since disease onset. There are …